ClinicalTrials.gov posted results on 15 September 2026 for a Phase 2 trial of nivolumab with doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin in patients with stage I-II Hodgkin lymphoma. The study enrolled 83 participants and reported progression-free survival of 96.48% in the treatment group.
Background
The study evaluated combination chemotherapy with nivolumab and brentuximab vedotin in patients with Ann Arbor stage I, IA, IB, II, or IIA Hodgkin lymphoma. The chemotherapy agents were doxorubicin, vinblastine, and dacarbazine. The supplied trial record describes nivolumab as a targeted agent that may interfere with cancer-cell growth and spread by enhancing the immune system. The record does not provide prior approval information or prevalence figures.
Trial design
This Phase 2 study, identified as NCT03233347, was listed as active, not recruiting, and enrolled 83 participants. The interventions were brentuximab vedotin, dacarbazine, doxorubicin, nivolumab, and vinblastine. The record lists no primary-outcome entries and does not identify a comparator arm. Posted measurements covered progression-free survival, overall survival, PET status, overall response rate, time to progression, and duration of response.
Key results
Progression-free survival in the combination-therapy group was 96.48% of patients alive and progression-free. Overall survival was reported as 100% of participants alive in two entries. The record counted 73 participants as PET negative and 4 participants as PET positive. Progression-free survival was 96.25% in the PET-negative group and 100% in the PET-positive group.
The overall response rate entry recorded 79 participants. Three participants converted from a partial response at the end of induction therapy to a complete response after brentuximab vedotin plus nivolumab. Median time to progression and median duration of response were both reported as NA. The listed measurements included 95% confidence-interval fields, but no confidence-interval values were supplied.
What this means
The posted results describe high progression-free and overall survival percentages for this combination in the enrolled stage I-II Hodgkin lymphoma population. However, the record lists no primary outcomes, comparator arm, p-values, or numerical confidence intervals. The findings therefore do not establish comparative efficacy from the supplied data.
Source
Source: ClinicalTrials.gov, registry results for the Phase 2 study “Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma,” posted 15 September 2026. Available at clinicaltrials.gov/study/NCT03233347.